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Chemotherapeutic drug resistance remains a major obstacle to the successful treatment of colon
cancer. Here, we show that 77 differentially expressed miRNAs were identiﬁed in SW1116/HCPT ver-
sus SW1116, and over-expressed miR-506 in SW1116/HCPT cells was validated. Then it was indicated
that PPARa is a common target of miR-506 by using a luciferase reporter assay. Our results also
demonstrated that cytotoxic ability of HCPT requires the concomitant presence of PPARa, and that
loss of PPARa expression imparts resistance to HCPTs anti-tumor effects. All together, our studies
indicate that miR-506 over-expression in established HCPT-resistant colon cancer cell line confers
resistance to HCPT by inhibiting PPARa expression, then providing a rationale for the development
of miRNA-based strategies for reversing resistance in HCPT-resistant colon cancer cells.
Crown Copyright  2011 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
Colon cancer is the third most common cancer for both men and
women in the United States [1]. Now, there is a growing impor-
tance of chemotherapy for malignant colon tumors. However,
resistance to anticancer drugs is still a major cause in the failure
of chemotherapy in cancer patients.
Inhibitors of topoisomerase I have demonstrated potent antitu-
mor activity in both preclinical and clinical trials [2–4]. Camptothe-
cin (CPT) was ﬁrst isolated from the bark of the Chinese/Tibetan
ornamental tree, Camptotheca acuminata. The development of cam-
ptothecin-like compounds (topotecan and irinotecan) as inhibitors
of topoisomerase I for the treatment of resistant tumors has gener-
ated clinical excitement in this new class of drugs. As anti-cancer
drugs, the efﬁcacy of camptothecin is limited by the onset of drug
resistance. Reversing such resistance could allow the decrease of
the dose necessary to eradicate the tumor, thus diminishing the side
effects of the drug.
In previous work, we established a new hydroxycamptothecin-
resistant cell line (SW1116/HCPT) fromhuman colon cancer cell line
SW1116 by treatment with step-wise increasing concentrations of
hydroxycamptothecin (HCPT) [5]. MicroRNAs play important rolesd by Elsevier B.V. on behalf of Fede
astroenterology, Renji Hospi-
00001, PR China. Fax: +86 21
online.sh.cn (Z.H. Ran).in the regulation of normal gene expression for developmental tim-
ing, cell proliferation, and apoptosis [6–8]. Despite strong evidence
that miRNAs are associated with cancer and are potential biomark-
ers for outcome, little is knownabouthowtheyaffect the responseof
a tumor to cytotoxic treatment.
In this work, to study the involvement of miRNAs in drug resis-
tance, we examined the differences in the miRNAs expression
proﬁles of hydroxycamptothecin-sensitive and hydroxycampto-
thecin-resistant cells by miRNA microarray analyses, then explor-
ing the potential role of speciﬁc miRNA in drug resistance to HCPT.2. Materials and methods
2.1. Cell culture
Human colon cancer cell line SW1116 (obtained from Academy
of Military Medical Science, Shanghai, China) and its hydroxycam-
ptothecin-resistant variant SW1116/HCPT [5] (established and
maintained in our laboratory) were cultured in RPMI-1640 med-
ium supplemented with 10% fetal bovine serum (FBS) in a 5%
CO2 humidiﬁed incubator at 37 C.
2.2. RNA extraction and miRNA microarray
Total RNA was extracted from SW1116 and SW1116/HCPT with
Trizol (Invitrogen). The isolated miRNAs from the two cell linesration of European Biochemical society. All rights reserved.
Table 1
Complementary pairs of oligonucleotides were designed to construct luciferase
reporter vectors.
Putative miRNA-binding sites Complementary pairs of
oligonucleotides
Position 3547-3553 of PPARa 30
UTR
30-ATTCCGTGGTCGTCGGCATTCGA-50
50CTAGTAAGGCACCAGCAGCCGTA-30
Mutant of position 3547-3553 30-ATAGGCACGTCGTCGGCATTCGA-50
50-CTAGTATCCGTGCAGCAGCCGTA-30
Position 7930-7937 of PPARa 30
UTR
30-AATTCCGTGAGTGATCATCTTTCGA-50
50CTAGTTAAGGCACTCACTAGTAGAA-30
Mutant of position 7930-7937 30-ATAAGGCAGAGTGATCATCTTTCGA-50
50-CTAGTATTCCGTCTCACTAGTAGAA-30
Position 8335-8341 of PPARa 30
UTR
30-AATTCCGTTTTGACATGGGATTCGA-50
50-CTAGTTAAGGCAAAACTGTACCCTA-
30
Mutant of position 8335-8341 30AAAAGGCTTTTGACATGGGATTCGA-50
50CTAGTTTTCCGAAAACTGTACCCTA-30
Position 2093-2099 of RXRa 30 UTR 30-ATTCCGTGGTCCACTTCGA-50
50-CTAGTAAGGCACCAGGTGA-30
Mutant of position 2093-2099 30-ATAGGCAGGTCCACTTCGA-50
50-CTAGTATCCGTCCAGGTGA-30
Position 3381-3387 of RXRa 30 UTR 30-AATTCCGTAACGATTCCTTTCGA-50
50-CTAGTTAAGGCATTGCTAAGGAA-30
Mutant of position 3381-3387 30-AAAAGGCTTTTGACATGGGATTCGA-50
50-CTAGTTTTCCGAAAACTGTACCCTA-30
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kit (Exiqon, Vedbaek, Denmark), and then hybridized respectively
on a miRCURYTM LNA microRNA Array (v 8.1, Exiqon) as described
[9]. Hybridization images were collected using a GenePix 4000B
laser scanner (Molecular Devices). Images were quantiﬁed by the
GenePix Pro 6.0 (Axon Instruments). Raw data were further auto-
matically processed in Microsoft Excel.
2.3. Real-time PCR analysis for miRNA
TaqMan MicroRNA Reverse Transcription kit and TaqMan
MicroRNA Assay were used to detect and quantify mature microR-
NA-506, microRNA-452, and microRNA-373⁄. Normalization was
performed with RNU6B. All primers were provided by Applied Bio-
systems. All reactions were performed according to manufacturer’s
protocols. Experiments were carried out in triplicate.
2.4. SYBR Green quantitative real-time reverse transcription-PCR
assays
The isolated RNA was DNase treated and reverse-transcribed
using First Strand cDNA Synthesis Kit (Fermentas) according to
the manufacturer’s instructions. RTQ-PCR was performed using
the SYBR Green method (Toyobo) and analyzed on an ABI PRISM
7900HT Sequence Detection System (Applied Biosystems). GAPDH
was employed as internal standard. Experiments were carried out
in triplicate.
2.5. miRNA target predictions
The analysis of miRNA predicted targets was carried out using
the algorithm TargetScanS [10]. The algorithm produced a list of
hundreds of target genes for miR-506 by searching for the presence
of conserved 8-mer and 7-mer sites matching the seed region of a
miR.
2.6. Reporter constructs
Three putative miRNA506-recognition elements from the
PPARa gene, two from RXR alpha and corresponding mutants were
cloned into the 30-untranslated region (UTR) of the luciferase gene
in the pMIR-REPORT luciferase vector (Ambion). The sense and
antisense strands of the oligonucleotide sequences (Table 1) were
annealed by adding 2 lg of each oligonucleotide to 46 lL of 1oli-
gonucleotide hybridization solution (100 mM potassium acetate,
30 mM HEPES, pH 7.4, and 2 mM magnesium acetate) and incu-
bated at 90 C for 3 min and then at 37 C for 1 h. The oligonucleo-
tide sequences were designed to carry the HindIII and SpeI sites at
their extremities facilitating ligation into the HindIII and SpeI sites
of pMIR-REPORT vector. The oligonucleotides used in the studies
were listed in Table.1. All constructs were conﬁrmed by DNA
sequence analysis.
2.7. Luciferase activity assay
SW1116 cells were cultured in 24-well plates and each trans-
fected with 200 ng of either Reporter constructs or corresponding
mutants together with 200 ng of pMIR-REPORT b-gal Control
Plasmid and 30 pmol of miR-506 precusor (Ambion) using Lipo-
fectmine 2000 (Invitrogen). Twenty-four hours following transfec-
tion, luciferase and b-galactosidase activities were assayed with
the Dual-Light Combined Reporter Gene Assay System (Applied
Biosystems) and Promega Turner TD-20/20 Luminometer. Lucifer-
ase activity was normalized to b-galactosidase activity. All assays
were performed in triplicate.2.8. Short hairpin RNA expression plasmids and stable transfection
We established a vector-based RNA interference expression sys-
tem using pRNAT-U6.1/Neo (Genscript, Piscataway, NJ, USA) small
interfering RNA (siRNA) expression vector. A shRNA expression vec-
tor against PPARa (pRNATU6.1-PPARAi) was prepared by cloning of
double-stranded oligonucleotides into the BamHI and HindIII sites
in the pRNAT-U6.1/Neo vector. The sequence of shRNA against
PPARawas 50 TGGGAAACATCCAAGAGAT 30, a second shRNA 50 CAT-
TGAACATCGAATGTAGAA 30, and a third shRNA 50 CGATCAAGTGA-
CATTGCTAAA 30. All of the constructs were conﬁrmed by DNA
sequencing. The pRNATU6.1-PPARAi vectorwas then used to induce
PPARa stable suppression in SW1116 cells using Lipofectmine 2000
(Invitrogen). Stable transfectants were selected by growing cells in
600 lg/ml G418; the cells (SW1116-PPARAi) that survived were
then expanded in the absence of G418 for additional studies.
2.9. Cytotoxicity assay
SW1116, SW1116-pMIF-miR-506 and SW1116-PPARAi cells
were seeded into 96-well plates at a density of 5000 cells/well in
RPMI 1640 medium with 10% FBS. The cells were treated with sev-
eral concentrations of HCPT for 72 h. After the incubation period,
the medium was removed, and 20 lL of 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/mL) were
added to each well, and plates were placed at 37 C for 4 h. At
the end of the incubation period, the untransformed MTT was re-
moved, and 100 lL dimethylsulfoxide was added to each well to
lyse the cells. Absorbance was measured at 570 nm using a 96-well
microplate reader (ELx-808, Cambrex, Baltimore, MD). The absor-
bance values were corrected for non-speciﬁc conversion of MTT
by preparation of blank wells containing all additions apart from
the cells. All of the experiments were performed in triplicate.
2.10. Apoptosis assay
Following 48 h of treatment, cells were harvested. Apoptotic
and necrotic cells were assayed in each sample using the Vybrant
3562 J.L. Tong et al. / FEBS Letters 585 (2011) 3560–3568apoptosis assay kit #2 and the protocol supplied by the manufac-
turer (Invitrogen). Each sample was evaluated by ﬂow cytometry
with a Coulter Epics XL ﬂow cytometer (Beckman-Coulter, Villep-
inte, France). Data were processed with Expo 32 cytometer soft-
ware (Beckman-Coulter). Experiments were done three times in
duplicate.
2.11. Western blot analysis
Western blots were done as previously described. The dilutions
of the primary antibodies were anti-PPARa (ab-2779, Cambridge,
MA) in 1:1000, and anti-GAPDH (Sc-32233, Santa Cruz Biotechnol-
ogy, Inc) in 1:5000.
2.12. Statistical analysis
Unpaired Student’s t test was performed for all experiments. All
data, unless stated otherwise, are expressed as mean ± standard
error of mean (SE). A P value of less than 0.05 was considered sta-
tistically signiﬁcant. SPSS Software, version 11 (SPSS Inc., Chicago,
IL, USA) was used for all statistical analyses.3. Results
3.1. Comparison of microRNA proﬁles between SW1116/HCPT and
SW1116
We analyzed miRNA expression proﬁles of SW1116 and its
hydroxycamptothecin-resistant variant SW1116/HCPT using a
miRNA microarray platform (Exiqon). Seventy-seven miRNAs
emerged as differentially expressed in SW1116/HCPT with respect
to SW1116. Speciﬁcally, 30 miRNAs were down-regulated and 47
miRNAs were up-regulated in SW1116/HCPT cells compared with
SW1116 (Fig. 1A and B). MiR-548d was the highest up-regulated
microRNA (124.55-fold), while miR-641 was the most highly
down-regulated one (60.20-fold).
At the same time, the differential pattern of gene expression
between SW1116 and SW1116/HCPT showed that PPARa was the
highest down-regulated transcript in resistant variant (about
404.1-fold) (Table S1). Combining data frommicroRNA chip results,
gene-chip results and the results of target prediction (Fig. 4A), two
down-regulated miRNAs (hsa-miR-452 and hsa-miR-373⁄) and one
up-regulated miRNA (hsa-miR-506) were selected for validation by
the TaqmanMicroRNA Assays. The expression level of hsa-miR-452
and hsa-miR-506 from real-time RT-PCR were consistent with
results from miRNA array analysis (Fig. 1C). However, the expres-
sion of hsa-miR-373⁄ was not detected by real-time RT-PCR.
3.2. Overexpression of miR-506 confers resistance to
hydroxycamptothecin in human colon cancer cell SW1116
Among above selected miRNAs, the most signiﬁcant changes in
the expression pattern were miR-506. Therefore, we further inves-
tigated the role of miR-506 in resistant variant SW1116/HCPT cells.
To investigate the possible inﬂuence of miR-506 status on the sen-
sitivity of colon cancer cells to HCPT, we ﬁrstly restored expression
of miR-506 in SW1116 cells through stable transfection of miR-506
expression vector PMIRH-506, which was constructed from vector
PMIRNA1 (System Biosciences, Mountain View, CA).. The expres-
sion of exogenous miR-506 in clone transfected with miR-506
was conﬁrmed by Taqman MicroRNA Assays. As shown in
Fig. 2A, the SW1116 cell line transfected with empty vector express
low levels of miR-506, whereas individual miR-506-transfected
clone express high levels of exogenous miR-506. Next, we did
MTT assays to determine whether the expression of miR-506would affect the sensitivity of SW1116 cells to HCPT. Dose-
response curves for HCPT treatment were determined in SW1116
and transfected cells, and the IC50 was calculated. The IC50 concen-
trations of HCPT were 92.6 lM and 145.5 lM in SW1116 transfec-
ted with empty vector and SW1116-pMIF-miR-506 cells (P < 0.05)
(Fig. 2B). Next, we examined the possible inhibitory effect of miR-
506 on the ability of HCPT to induce tumor cell apoptosis. 100 lM
and 150 lM concentrations of HCPT were used to treat both cell
lines. At the same concentrations of HCPT, the ﬂow cytometric
analysis indicates that in SW1116-pMIF-miR-506 cells, the apopto-
tic rate induced by HCPT alone was signiﬁcant lower than that of
treatment in the parental SW1116 cells (150 lM: 18.2 ± 4.7% vs
33.6 ± 3.9%) (P < 0.05) (Fig. 2C). We also performed the same exper-
iment in SW1116/HCPT by transfection with antisense (anti)-miR-
506 (Shanghai GenePharma Co., Ltd). Real-time RT-PCR analysis
conﬁrmed 80.7 ± 19.3% reduction in miR-506 levels after introduc-
tion of anti-miR-506 compared with negative control group. The
IC50 concentrations of HCPT were 812.3 lM and 393.8 lM in
SW1116/HCPT transfected with negative control and anti-
miR-506. A signiﬁcant elevated level of apoptosis (37.9 ± 2.2)%
was observed after 48 h transfection with anti-miR-506 compared
with the negative control group (18.5 ± 2.1)% (P < 0.05) in SW1116/
HCPT cell by treatment with HCPT (800 lM) (Fig. 3).3.3. MicroRNA 506 regulates expression of PPARa in
hydroxycamptothecin-resistant human colon cancer cells
The differential expression proﬁles observed in the microarray
experiments (Table S1) were conﬁrmed for two representative
genes (PPARa and RXRa) using RTQ-PCR. As shown in Fig. 4B, dif-
ferential expression of these genes was conﬁrmed. Therefore,
PPARa and RXRa became our research interest, because of the
strikingly differential expression. Furthermore, the high expression
level of PPARa was also reported in an adriamycin-resistant hepa-
tocellular carcinoma cell line HepG2/ ADM [11].
Using bioinformatic tools (TargetScanS), we searched for poten-
tial mRNA targets of human miR-506. Among the candidates tar-
geted, 30-UTR of human PPARa contains three putative regions
(nucleotides 3547-3553, 7930-7936, 8335-8341) that matches to
the seed sequence of hsa-miR-506, two putative regions for RXRa
(nucleotides 2093-2099, 3381-3387) (Fig. 4A). To investigate the
inﬂuence of miR-506 on predicted mRNA targets, we transfected
the pre-miR-506 (Ambion) into SW1116 cells (which expressed
low level of miR-506) and searched for changes of PPARa protein
levels. We found that introduction of miR-506 precursor decreased
PPARa protein levels in a dose-dependent manner (Fig. 4C). Then
we transfected the antisense (AS)-miR-506 (Shanghai GenePharma
Co., Ltd) into SW1116/HCPT cells (which expressed high level of
miR-506), we also found that introduction of AS-miR-506 in-
creased PPARa protein levels in a dose-dependent manner, namely
an inverse relationship between miR-506 and PPARa (Fig. 4C).
To examine whether PPARa and RXRa are indeed the targets of
miR-506, luciferase constructs were made by ligating oligonucleo-
tides containing the wild-type or mutant putative target site of the
PPARa and RXRa 30 UTR into the multi-cloning site of the pMIR
Reporter Luciferase vector. Both the wild-type and the mutant
reporters were introduced into SW1116 cells, pMIR-REPORT
Beta-gal was used as a reference control. For 3 report vectors of
PPARa, the changes of luciferase were about 2.68 ± 0.55 fold,
1.43 ± 0.22 fold and 1.34 ± 0.20 fold for position 7930-7937, posi-
tion 3547-3553 and position 8335-8341, respectively. However,
for 2 report vectors of RXRa, the changes of luciferase were all
insigniﬁcant (Fig. 4D). These ﬁndings indicate that miR-506 nega-
tively regulates the expression of PPARa through its three pre-
dicted binding sites, not for RXRa.
Fig. 1. Microarray analyses indicate that miRNAs are dysregulated in HCPT-resistant cells. (A) Up-regulated miRNAs from miRNA microarray of SW1116/HCPT versus
SW1116 cells (fold change > 2). (B) Down-regulated miRNAs from miRNA microarray of SW1116/HCPT versus SW1116 cells (fold change > 2). (C) Changes in expression of
hsa-miR-452, hsa-miR-506, hsa-miR-373⁄ were conﬁrmed by RTQ-PCR. Means from triplicate experiments in all cases; bars, SE. ⁄⁄P < 0.01.
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resistance in human colon cancer cells
To evaluate the potential correlation between PPARa mRNA/
protein expression and HCPT sensitivity in colon cancer cells, we
ﬁrst examined the expression of endogenous PPARamRNA/protein
in HCPT-sensitive and HCPT-resistant cell lines by real-time PCR
(Fig. 4B) and Western blot analysis (Fig. 6B). A high level of PPARa
mRNA/protein was detected in the colon cancer cell line SW1116
that was established from tumors sensitive to HCPT, but low level
of PPARa mRNA/protein expression was detected in the HCPT-
resistant SW1116/HCPT cell line, suggesting that PPARa is involved
in HCPT-induced resistance in vitro.
To further assess the biological involvement of PPARa activity
in HCPT-mediated cytotoxicity, we began by analyzing individual
and combined effect of PPARa ligands and HCPT. We ﬁrst investi-
gated the sensitivity of SW1116/HCPT cells to a PPARa agonist
wy-14643 (BIOMOL) as a single agent. As shown in Fig. 5A, wy-
14643 only slightly inhibited the proliferation of SW1116/HCPT
cells. Surprisingly, we found that wy-14643 strongly enhanced
HCPT-induced inhibition of cell vitality in a synergistic manner.
Furthermore, we showed that the above effect was in a dose-
dependent manner. At the same time, wy-14643 also potentiates
HCPT-induced apoptosis in a dose-dependent manner (Fig. 5B).Next, the effects of treatment with HCPT and PPARa antagonist
MK 886 (SIGMA), alone or in combination were examined in
SW1116 cells. We found that MK 886 alone could inhibit cell vital-
ity and induce apoptosis in SW1116 cells, and pretreatment with
MK 886 for 24 h before addition of HCPT enhanced the cytotoxicity
of HCPT (Fig. 5C and D)
According to our hypothesis, inhibition of PPARa by treatment of
MK 886 would augment resistance of SW1116 to cytotoxicity of
HCPT. However, the above data did not support our initial idea.
We supposed that whether there was non-speciﬁc effects of the
antagonist MK 886 used at this concentration on cell vitality. To ad-
dress this problem, we used RNAi vectors to inhibit PPARa expres-
sion in stably transfected SW1116 cells. After screening by
culturing with G418, expression of PPARa mRNAs in the G418-
selected cell pools was veriﬁed by semi-quantitative RT-PCR.
Following identiﬁcation of a correctly targeted transfectant, the
expression level of protein was further immunobloted. As Fig. 6A
shows, real-time RT-PCR analysis conﬁrmed 94.1 ± 3.4% (P < 0.05)
reduction in PPARa mRNA levels in the SW1116-PPARAi clones III
relative to the vector control. Furthermore, the stably transfected
clone expressing shRNA against PPARa displayed a 68.9 ± 8.3%
reduction in protein level (Fig. 6B).
To test the sensitivity of SW1116-PPARAi clones to HCPT,
SW1116-PPARAi clones and vector-transfected cells were exposed
Fig. 2. Ectopic expression of miR-506 induces resistance to HCPT-induced apop-
tosis in SW1116 cells. (A) Ectopic expression of miR-506. SW1116 cells which
express low levels of endogenous miR-506 were transfected with PMIRH-506 or
empty vector (PMIRNA1). After 15 d under G418 selection, the expression level of
mir-506 was determined by quantitative RT-PCR in stable cells versus cells
transfected with control vector. Columns, mean; bars, SE. (B) MTT assay. The
SW1116-pMIF-miR-506 cells or SW1116 transfected with empty vector were
treated with different concentrations of HCPT for 3 days and examined for cell
viability. (C) Flow cytometry. The vector-transfected and miR-506–transfected cells
were treated with 100 lM and 150 lMHCPT, after 48 h of the treatment, cells were
labeled with Annexin V and analyzed by ﬂow cytometry. ⁄P < 0.05, ⁄⁄P < 0.01.
Fig. 3. Inhibition of miR-506 expression decrease resistance to HCPT-induced
apoptosis in SW1116/HCPT cells. (A) Inhibition of miR-506 expression. SW1116/
HCPT cells which express high levels of endogenous miR-506 were transfected with
anti-miR-506 or negative control (NE) alone. After 48 h, the cells were harvested for
the miR-506 quantitative analysis. Columns, mean; bars, SE. (B) MTT assay. The
SW1116/HCPT cells transfected with NE and anti-miR-506 were treated with
different concentrations of HCPT for 3 days and examined for cell viability. (C) Flow
cytometry. The Anti-miR-506-transfected and NE–transfected cells were treated
with 800 lM HCPT, after 48 h of the treatment, cells were labeled with Annexin V
and analyzed by ﬂow cytometry. ⁄P < 0.05, ⁄⁄P < 0.01.
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by MTT assay. As seen ﬁgure, the IC50 concentrations of HCPT were
87.0 lM and 225.9 lM in SW1116 and transfected cells (P < 0.05)
(Fig. 6C). Next, we examined the possible inhibitory effect of
PPARa on the ability of HCPT to induce tumor cell apoptosis.
150 lM and 300 lM concentrations of HCPT were used to treat
both cell line. At the same concentrations of HCPT, the ﬂow cyto-
metric analysis indicates that in SW1116-PPARAi cell line, the
apoptotic rate (Fig. 6D) induced by HCPT alone was signiﬁcant low-
er than that of treatment in the parental SW1116 cells.4. Discussion
Recently, accumulating evidence has indicated that altered
miRNA level resulted from mutation or aberrant expression is
correlated with various human cancers [12,13]. The role of miRNAs
in multi-drug resistance was also reported in some studies. Xia et
al. suggest that miR-15b and miR-16 could play a vital role in the
development of MDR in gastric cancer cells at least in part by mod-
Fig. 4. MiR-506 directly targets PPAR alpha. (A) The predicted sites of miR-506 (Bottom) hybridization to the PPAR alpha and RXRA 30-UTR region (top) as detected by
TargetScan. (B) PPAR alpha and RXRA mRNA levels are signiﬁcantly different in resistant cell line versus its parent cell line as determined by RT-PCR. Left, RXRA; right, PPAR
alpha. (C) Effects of pre-miR-506 and AS-miR-506 on PPAR alpha protein expression. SW1116 cells were transfected with pre-miR-506 and SW1116/HCPT cells were
transfected with AS-miR-506 both at a ﬁnal concentration of 100, 300 and 600 nmol/L. PPAR alpha protein level were determined by western blot analysis as described in
Section 2. Columns, means for three replicate determinations for each treatment group; bars, SE. The control treatment groups were transfected with 100 nmol/L of scrambled
oligonucleotide and served as controls for the experiments. (D) miR-506 inhibits wild-type but not mutated ppar alpha-30-UTR reporter activity. Expression of luciferase with
the putative miR-506 target sites in wild-type (wt) or mutated 30-UTR from PPAR alpha (right) and RXRA (left) were measured in a luminometer and shown as a fraction of
control. Relative luciferase activity was normalized to the scrambled oligonucleotide control. Columns, mean; bars, SE. ⁄P < 0.05, ⁄⁄P < 0.01.
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the roles of microRNAs in the regulation of drug resistance medi-
ated by MDR1/P-glycoprotein, and suggest the potential for target-
ing miR-27a and miR-451 as a therapeutic strategy for modulating
MDR in cancer cells [15].In this study, we identiﬁed that miR-506 was over-expressed in
established HCPT-resistant colon cancer cell line SW1116/HCPT.
Through bioinformatic prediction using targetScanS software, 3
sites in PPARa 30 UTR region and 2 sites in RXRa 30 UTR region be-
come our interests. Moreover, PPARs all bind as heterodimers with
Fig. 5. Antiproliferative actions of hydroxycamptothecin in combination with WY 14643 or MK886 in human colon cancer cell line SW1116 and its HCPT-resistant variant
SW1116/HCPT. (A) Effect of WY 14643 and HCPT treatment on cell viability of SW1116/HCPT cells. Cells were treated with either HCPT (2.4 mg/L) alone, or treated
simultaneously with WY 14643 (0, 50, 250, 500 lmol/L) for 48 h and then analyzed by MTT assay. Columns, mean; bars, SE. (B) Sensitization of SW1116/HCPT cells to HCPT–
induced andWY 14643-induced apoptosis as determined by ﬂow cytometry analysis after 48 h treatment with HCPT (2.4 mg/L) alone, or combination of HCPT andWY 14643.
Increased apoptotic response was evident in combination treatment group relative to untreated control or single-agent treated group. (C) Drug effects of MK886 or
combination effects of MK886 plus HCPT on the colon cancer cell line SW1116. (D) MK886 potentiates apoptosis of SW1116 cells in response to HCPT in a dose-dependent
manner. ﬂow cytometry analysis cell apoptosis after 48 h treatment with HCPT (150 lg/L) alone, or the combination of HCPT and MK886. ⁄⁄P < 0.01.
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peroxisome proliferator response elements (PPRE) consisting of a
direct repeat of the hormone receptor response element half-site
spaced by one nucleotide in target genes [16]. Using luciferase
assays, we documented a direct link between miR-506 and the
putative target PPARa.
To date, the role of miR-506 in tumor cell is not clear. Zhao et al.
found that expression of miR-506 was reduced in 16HBE-T trans-
formed malignant human bronchial epithelial cells compared with
16HBE normal human bronchial epithelial cells and revealed that
miR-506 acts as an anti-oncogenic miRNA (anti-oncomir) in malig-
nantly transformed cells [17]. However, we show that miR-506
over-expression in established HCPT-resistant colon cancer cell line
SW1116/HCPT confers resistance to HCPT by inhibiting PPARa
expression. Peroxisome proliferator-activated receptors (PPARs)
are steroid nuclear receptors that regulate diverse biological pro-
cesses. Activation of PPARa has been reported to improve levels
of triglycerides, HDL, and the overall atherogenic plasma lipid pro-
ﬁle, while also potentially modulating inﬂammation as well insulin
resistance itself [18,19]. Recently, it has been found that PPARsmay
also regulate the expression of some MDR proteins [20]. One of themajor changes in the phenotype of MDR cells is a decreased accu-
mulation of cytotoxic drugs, mainly due to P-glycoprotein over-
expression, which uses ATP to extrude chemotherapeutic agents
from the cells [21]. Such an energy-dependent process may require
a high energy demand with an enhancement of energy-yielding
pathways [22]. These pathways are strongly associated with ER-
dependent signaling and signiﬁcantly predict response to tamoxi-
fen treatment, as measured by disease-free and overall survival
[23]. Furthermore, some MDR proteins were regulated by PPARa
[24,25]. Therefore, we hypothesized that PPARa play an important
role in resistance of colon cancer cell to HCPT.
In efforts to explore the role of PPARa in vitro, most of the recent
studies employed pharmacological approaches. WY 14643 is a po-
tent exogenous PPARa agonist and MK886 is a PPARa antagonist.
Here, we found that WY 14643 was able to induce apoptosis in a
synergistic manner with HCPT, thereby enhancing the antitumor
effect of HCPT in SW1116/HCPT cells. However, in SW1116 cells,
synergistic cytotoxicity was also observed when MK 886 was
administered with HCPT. The ‘‘off-target’’ effects of PPARa antago-
nist MK 886 necessitated the use of other approaches to evaluate
the consequences of PPARa inactivation. Using RNAi techniques
Fig. 6. PPARa down-regulation reduces sensitivity to HCPT in SW1116 cells. (A) SW1116 cells were stably transfected with either empty shRNA vector (SW1116-pRNAT-
U6.1/Neo) (C) or PPARa shRNA-expressing shRNA vector (SW1116-PPARAi). PPARa expression in these clones (I, II, III) was analyzed by using semi-quantitative RT-PCR. (B)
Expression of PPARa protein in SW1116-pRNAT-U6.1/Neo clone and SW1116-PPARAi clone III. Whole-cell lysates were used to detect the protein level of PPARa by
immunoblot analysis (top) with GADPH as loading control (bottom). (C) SW1116-pRNAT-U6.1/Neo clone and SW1116-PPARAi clone were treated with concentrations of
HCPT range 0 lmol/L from 320 lmol/L, and cell viability was determined 72 h later using the MTT assay. The IC50 values were calculated. Each assay was repeated at least
thrice. (D) Analysis of Annexin V and propidium iodide staining in SW1116-pRNAT-U6.1/Neo clone and SW1116-PPARAi clone by ﬂow cytometry after treatment with 150 or
300 lmol/L HCPT for 48 h. ⁄P < 0.05, ⁄⁄P < 0.01.
J.L. Tong et al. / FEBS Letters 585 (2011) 3560–3568 3567to inhibit PPARa expression, we demonstrated that down-regula-
tion of PPARa leads to a decrease in cellular proliferation and a
simultaneous increase in HCPT-induced apoptosis in SW1116 cells.
Interestingly, direct siRNA-mediated repression of PPARalpha or
overexpression of miR-506 had similar effects on cellular prolifer-
ation and apoptosis upon HCPT treatment. This further suggests
that PPARa is a true target gene of miR-506.
In summary, we show that miR-506 over-expression in estab-
lished HCPT-resistant colon cancer cell line SW1116/HCPT confers
resistance to HCPT by inhibiting PPARa expression.
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